Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | CLPP | Q16740 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410796 | 0.92 | PTGDR2 (0.47) | NPSR1PTGDR2GAAHTTGPR55 | |
| SCHEMBL4709565 | 0.87 | NPSR1 (0.56) | NPSR1PTGDR2GAAHTTGPR55 | |
| SCHEMBL4423000 | 0.86 | PTGDR2 (0.55) | NPSR1PTGDR2GAAHTTGPR55 | |
| SCHEMBL4415654 | 0.86 | PTGDR2 (0.42) | NPSR1PTGDR2GAAHTTGPR55 | |
| SCHEMBL4413377 | 0.85 | GABRA1 (0.45) | PTGDR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4410915 | 0.83 | GABRA1 (0.46) | PTGDR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4412817 | 0.82 | GABRA1 (0.43) | PTGDR2GAAGABRA1GABRG2GABRB3 | |
| SCHEMBL4410766 | 0.82 | GABRA1 (0.42) | PTGDR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4709544 | 0.81 | NPSR1 (0.47) | NPSR1PTGDR2GAAHTTGPR55 | |
| SCHEMBL4410792 | 0.81 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | claimed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | claimed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | claimed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | claimed |
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | disclosed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | PDE12, PDE4B, PDE2A | NPSR1 285/4885PTGDR2 48/4885GAA 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.